Roche — Fact Sheet (November 2022)

2 slides from Roche's fact sheet, November 2022

Slide 1: Elecsys Anti-SARS-CoV-2 S: course of markers in SARS-CoV-2 infection
Estimated course of markers in SARS-CoV-2 infection32 Incubation Symptoms Recovery Convalescence Potential long-term immunity period SARS-CoV-2 RNA IgG antibodies relative concentration IgM antibodies Elecsys® Anti-SARS-CoV-2 S IgA antibodies Immunoassay for the quantitative determination of antibod
Slide 2: Elecsys Anti-SARS-CoV-2 S assay, clinical sensitivity and vaccination response
After infection or vaccination, the binding strength of antibodies Elecsys® Anti-SARS-CoV-2 S is an immunoassay for the in vitro Clinical sensitivity31 Detection of antibodies induced by active immunization with vaccines against SARS-CoV-231 to antigens increases over time – a process called affinit